Us Bancorp \De\ Intra Cellular Therapies, Inc. Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 3,621 shares of ITCI stock, worth $460,301. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,621

Previous 7,951 54.46%

Holding current value

$460,301

Previous $581,000 48.02%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$71.19 - $91.57 $308,252 - $396,498	-4,330 Reduced 54.46%	3,621 $302,000
Q3 2024 Oct 28, 2024	BUY	$67.99 - $80.84 $17,065 - $20,290	251 Added 3.26%	7,951 $581,000
Q2 2024 Aug 06, 2024	BUY	$64.76 - $79.84 $326,843 - $402,952	5,047 Added 190.24%	7,700 $527,000
Q1 2024 May 07, 2024	BUY	$64.37 - $75.65 $60,314 - $70,884	937 Added 54.6%	2,653 $183,000
Q4 2023 Feb 09, 2024	BUY	$46.37 - $73.65 $695 - $1,104	15 Added 0.88%	1,716 $122,000
Q3 2023 Nov 03, 2023	SELL	$52.09 - $64.1 $2,344 - $2,884	-45 Reduced 2.58%	1,701 $88,000
Q2 2023 Aug 09, 2023	BUY	$54.67 - $66.44 $5,740 - $6,976	105 Added 6.4%	1,746 $110,000
Q1 2023 May 09, 2023	BUY	$43.8 - $56.99 $14,804 - $19,262	338 Added 25.94%	1,641 $88,000
Q4 2022 Feb 13, 2023	SELL	$44.07 - $54.45 $2,423 - $2,994	-55 Reduced 4.05%	1,303 $68,000
Q3 2022 Oct 27, 2022	BUY	$42.7 - $59.99 $36,807 - $51,711	862 Added 173.79%	1,358 $63,000
Q2 2022 Aug 01, 2022	BUY	$43.0 - $65.64 $10,320 - $15,753	240 Added 93.75%	496 $28,000
Q1 2022 May 11, 2022	BUY	$38.74 - $62.09 $271 - $434	7 Added 2.81%	256 $16,000
Q2 2021 Aug 05, 2021	SELL	$29.3 - $44.5 $498 - $756	-17 Reduced 6.39%	249 $10,000
Q4 2020 Feb 04, 2021	BUY	$23.34 - $32.22 $980 - $1,353	42 Added 18.75%	266 $8,000
Q3 2020 Nov 10, 2020	SELL	$17.61 - $31.86 $16,377 - $29,629	-930 Reduced 80.59%	224 $6,000
Q2 2020 Aug 07, 2020	SELL	$14.35 - $26.64 $6,959 - $12,920	-485 Reduced 29.59%	1,154 $30,000
Q1 2020 May 13, 2020	BUY	$12.31 - $33.12 $13,676 - $36,796	1,111 Added 210.42%	1,639 $25,000
Q4 2019 Feb 04, 2020	BUY	$7.26 - $38.49 $2,758 - $14,626	380 Added 256.76%	528 $18,000
Q3 2019 Nov 08, 2019	SELL	$7.47 - $14.03 $12,011 - $22,560	-1,608 Reduced 91.57%	148 $1,000
Q2 2019 Aug 13, 2019	BUY	$10.65 - $14.29 $10,628 - $14,261	998 Added 131.66%	1,756 $23,000
Q1 2019 May 08, 2019	SELL	$10.9 - $14.09 $7,739 - $10,003	-710 Reduced 48.37%	758 $9,000
Q4 2018 Feb 13, 2019	SELL	$10.36 - $20.96 $12,680 - $25,655	-1,224 Reduced 45.47%	1,468 $17,000
Q2 2018 Aug 08, 2018	BUY	$17.33 - $23.4 $16,758 - $22,627	967 Added 56.06%	2,692 $48,000
Q1 2018 May 08, 2018	SELL	$15.16 - $25.49 $2,289 - $3,848	-151 Reduced 8.05%	1,725 $37,000
Q4 2017 Feb 02, 2018	SELL	$14.27 - $16.79 $970 - $1,141	-68 Reduced 3.5%	1,876 $27,000
Q3 2017 Nov 13, 2017	BUY	$10.77 - $22.1 $20,936 - $42,962	1,944	1,944 $31,000

Others Institutions Holding ITCI

# of Institutions

387

Shares Held

85.9M

Call Options Held

231K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account